Abstract
Hypereosinophilic syndromes (HES) are rare and heterogenous disorders characterized by persistent blood eosinophilia (absolute eosinophil count [AEC] >1500 cells/μL) and eosinophil-mediated end-organ involvement, including but not limited to dermatologic, pulmonary, gastrointestinal, and cardiovascular manifestations, impacting quality of life. Current treatment of symptomatic HES includes corticosteroids and corticosteroid-sparing agents. Patients often experience treatment-limiting or intolerable adverse effects despite available therapies and need additional therapeutic options.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
